English
简体中文
Total: £ 56.28
Published Date: 2025-11-07 | Pages: 131 | Tables: 137 | Medical Care
The global Extracellular Vesicles Based Liquid Biopsy market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
From a downstream perspective, Therapeutic Monitoring accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Extracellular Vesicles Based Liquid Biopsy leading manufacturers including Bio-Techne, Thermo Fisher Scientific, Qiagen, Exosome Diagnostics, Aethlon Medical, System Biosciences, NanoSomix, Norgen Biotek, Hitachi Chemical, Lonza Group, etc., dominate supply; the top five capture approximately % of global revenue, with Bio-Techne leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Extracellular Vesicles Based Liquid Biopsy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Bio-Techne
Thermo Fisher Scientific
Qiagen
Exosome Diagnostics
Aethlon Medical
System Biosciences
NanoSomix
Norgen Biotek
Hitachi Chemical
Lonza Group
Stemcell Technologies
Aruna Bio
Evomic Science
Izon Science
Exovita Biosciences
Segment by Type
Blood-derived Liquid Biopsy
Urine-derived Liquid Biopsy
Saliva-derived Liquid Biopsy
Other
Segment by Application
Therapeutic Monitoring
Medical Diagnostics
Biological Research
Other
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Extracellular Vesicles Based Liquid Biopsy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Extracellular Vesicles Based Liquid Biopsy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Extracellular Vesicles Based Liquid Biopsy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Blood-derived Liquid Biopsy
1.2.3 Urine-derived Liquid Biopsy
1.2.4 Saliva-derived Liquid Biopsy
1.2.5 Other
1.3 Market Segmentation by Application
1.3.1 Global Extracellular Vesicles Based Liquid Biopsy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Therapeutic Monitoring
1.3.3 Medical Diagnostics
1.3.4 Biological Research
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Extracellular Vesicles Based Liquid Biopsy Revenue Estimates and Forecasts 2020-2031
2.2 Global Extracellular Vesicles Based Liquid Biopsy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Extracellular Vesicles Based Liquid Biopsy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Extracellular Vesicles Based Liquid Biopsy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Blood-derived Liquid Biopsy Market Size by Players
3.3.2 Urine-derived Liquid Biopsy Market Size by Players
3.3.3 Saliva-derived Liquid Biopsy Market Size by Players
3.3.4 Other Market Size by Players
3.4 Global Extracellular Vesicles Based Liquid Biopsy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Extracellular Vesicles Based Liquid Biopsy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Extracellular Vesicles Based Liquid Biopsy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Extracellular Vesicles Based Liquid Biopsy Market Size by Type (2020-2031)
6.4 North America Extracellular Vesicles Based Liquid Biopsy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Extracellular Vesicles Based Liquid Biopsy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Extracellular Vesicles Based Liquid Biopsy Market Size by Type (2020-2031)
7.4 Europe Extracellular Vesicles Based Liquid Biopsy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Extracellular Vesicles Based Liquid Biopsy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Extracellular Vesicles Based Liquid Biopsy Market Size by Type (2020-2031)
8.4 Asia-Pacific Extracellular Vesicles Based Liquid Biopsy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Extracellular Vesicles Based Liquid Biopsy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Extracellular Vesicles Based Liquid Biopsy Market Size by Type (2020-2031)
9.4 Central and South America Extracellular Vesicles Based Liquid Biopsy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Extracellular Vesicles Based Liquid Biopsy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Extracellular Vesicles Based Liquid Biopsy Market Size by Type (2020-2031)
10.4 Middle East and Africa Extracellular Vesicles Based Liquid Biopsy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Extracellular Vesicles Based Liquid Biopsy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Bio-Techne
11.1.1 Bio-Techne Corporation Information
11.1.2 Bio-Techne Business Overview
11.1.3 Bio-Techne Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.1.4 Bio-Techne Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.1.5 Bio-Techne Extracellular Vesicles Based Liquid Biopsy Revenue by Product in 2024
11.1.6 Bio-Techne Extracellular Vesicles Based Liquid Biopsy Revenue by Application in 2024
11.1.7 Bio-Techne Extracellular Vesicles Based Liquid Biopsy Revenue by Geographic Area in 2024
11.1.8 Bio-Techne Extracellular Vesicles Based Liquid Biopsy SWOT Analysis
11.1.9 Bio-Techne Recent Developments
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Corporation Information
11.2.2 Thermo Fisher Scientific Business Overview
11.2.3 Thermo Fisher Scientific Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.2.4 Thermo Fisher Scientific Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.2.5 Thermo Fisher Scientific Extracellular Vesicles Based Liquid Biopsy Revenue by Product in 2024
11.2.6 Thermo Fisher Scientific Extracellular Vesicles Based Liquid Biopsy Revenue by Application in 2024
11.2.7 Thermo Fisher Scientific Extracellular Vesicles Based Liquid Biopsy Revenue by Geographic Area in 2024
11.2.8 Thermo Fisher Scientific Extracellular Vesicles Based Liquid Biopsy SWOT Analysis
11.2.9 Thermo Fisher Scientific Recent Developments
11.3 Qiagen
11.3.1 Qiagen Corporation Information
11.3.2 Qiagen Business Overview
11.3.3 Qiagen Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.3.4 Qiagen Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.3.5 Qiagen Extracellular Vesicles Based Liquid Biopsy Revenue by Product in 2024
11.3.6 Qiagen Extracellular Vesicles Based Liquid Biopsy Revenue by Application in 2024
11.3.7 Qiagen Extracellular Vesicles Based Liquid Biopsy Revenue by Geographic Area in 2024
11.3.8 Qiagen Extracellular Vesicles Based Liquid Biopsy SWOT Analysis
11.3.9 Qiagen Recent Developments
11.4 Exosome Diagnostics
11.4.1 Exosome Diagnostics Corporation Information
11.4.2 Exosome Diagnostics Business Overview
11.4.3 Exosome Diagnostics Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.4.4 Exosome Diagnostics Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.4.5 Exosome Diagnostics Extracellular Vesicles Based Liquid Biopsy Revenue by Product in 2024
11.4.6 Exosome Diagnostics Extracellular Vesicles Based Liquid Biopsy Revenue by Application in 2024
11.4.7 Exosome Diagnostics Extracellular Vesicles Based Liquid Biopsy Revenue by Geographic Area in 2024
11.4.8 Exosome Diagnostics Extracellular Vesicles Based Liquid Biopsy SWOT Analysis
11.4.9 Exosome Diagnostics Recent Developments
11.5 Aethlon Medical
11.5.1 Aethlon Medical Corporation Information
11.5.2 Aethlon Medical Business Overview
11.5.3 Aethlon Medical Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.5.4 Aethlon Medical Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.5.5 Aethlon Medical Extracellular Vesicles Based Liquid Biopsy Revenue by Product in 2024
11.5.6 Aethlon Medical Extracellular Vesicles Based Liquid Biopsy Revenue by Application in 2024
11.5.7 Aethlon Medical Extracellular Vesicles Based Liquid Biopsy Revenue by Geographic Area in 2024
11.5.8 Aethlon Medical Extracellular Vesicles Based Liquid Biopsy SWOT Analysis
11.5.9 Aethlon Medical Recent Developments
11.6 System Biosciences
11.6.1 System Biosciences Corporation Information
11.6.2 System Biosciences Business Overview
11.6.3 System Biosciences Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.6.4 System Biosciences Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.6.5 System Biosciences Recent Developments
11.7 NanoSomix
11.7.1 NanoSomix Corporation Information
11.7.2 NanoSomix Business Overview
11.7.3 NanoSomix Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.7.4 NanoSomix Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.7.5 NanoSomix Recent Developments
11.8 Norgen Biotek
11.8.1 Norgen Biotek Corporation Information
11.8.2 Norgen Biotek Business Overview
11.8.3 Norgen Biotek Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.8.4 Norgen Biotek Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.8.5 Norgen Biotek Recent Developments
11.9 Hitachi Chemical
11.9.1 Hitachi Chemical Corporation Information
11.9.2 Hitachi Chemical Business Overview
11.9.3 Hitachi Chemical Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.9.4 Hitachi Chemical Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.9.5 Hitachi Chemical Recent Developments
11.10 Lonza Group
11.10.1 Lonza Group Corporation Information
11.10.2 Lonza Group Business Overview
11.10.3 Lonza Group Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.10.4 Lonza Group Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Stemcell Technologies
11.11.1 Stemcell Technologies Corporation Information
11.11.2 Stemcell Technologies Business Overview
11.11.3 Stemcell Technologies Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.11.4 Stemcell Technologies Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.11.5 Stemcell Technologies Recent Developments
11.12 Aruna Bio
11.12.1 Aruna Bio Corporation Information
11.12.2 Aruna Bio Business Overview
11.12.3 Aruna Bio Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.12.4 Aruna Bio Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.12.5 Aruna Bio Recent Developments
11.13 Evomic Science
11.13.1 Evomic Science Corporation Information
11.13.2 Evomic Science Business Overview
11.13.3 Evomic Science Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.13.4 Evomic Science Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.13.5 Evomic Science Recent Developments
11.14 Izon Science
11.14.1 Izon Science Corporation Information
11.14.2 Izon Science Business Overview
11.14.3 Izon Science Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.14.4 Izon Science Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.14.5 Izon Science Recent Developments
11.15 Exovita Biosciences
11.15.1 Exovita Biosciences Corporation Information
11.15.2 Exovita Biosciences Business Overview
11.15.3 Exovita Biosciences Extracellular Vesicles Based Liquid Biopsy Product Features and Attributes
11.15.4 Exovita Biosciences Extracellular Vesicles Based Liquid Biopsy Revenue and Gross Margin (2020-2025)
11.15.5 Exovita Biosciences Recent Developments
12 Extracellular Vesicles Based Liquid BiopsyIndustry Chain Analysis
12.1 Extracellular Vesicles Based Liquid Biopsy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Extracellular Vesicles Based Liquid Biopsy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Extracellular Vesicles Based Liquid Biopsy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Extracellular Vesicles Based Liquid Biopsy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Extracellular Vesicles Based Liquid Biopsy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Extracellular Vesicles Based Liquid Biopsy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Extracellular Vesicles Based Liquid Biopsy Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Extracellular Vesicles Based Liquid Biopsy Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Extracellular Vesicles Based Liquid Biopsy Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Extracellular Vesicles Based Liquid Biopsy Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Extracellular Vesicles Based Liquid Biopsy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Extracellular Vesicles Based Liquid Biopsy as of 2024)
Table 11. Global Extracellular Vesicles Based Liquid Biopsy Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Extracellular Vesicles Based Liquid Biopsy Companies Headquarters
Table 13. Global Extracellular Vesicles Based Liquid Biopsy Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Extracellular Vesicles Based Liquid Biopsy Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Extracellular Vesicles Based Liquid Biopsy Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Extracellular Vesicles Based Liquid Biopsy Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Extracellular Vesicles Based Liquid Biopsy Revenue by Application (2026-2031) & (US$ Million)
Table 21. Extracellular Vesicles Based Liquid Biopsy High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Extracellular Vesicles Based Liquid Biopsy Growth Accelerators and Market Barriers
Table 25. North America Extracellular Vesicles Based Liquid Biopsy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Extracellular Vesicles Based Liquid Biopsy Growth Accelerators and Market Barriers
Table 27. Europe Extracellular Vesicles Based Liquid Biopsy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Extracellular Vesicles Based Liquid Biopsy Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Extracellular Vesicles Based Liquid Biopsy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Extracellular Vesicles Based Liquid Biopsy Investment Opportunities and Key Challenges
Table 31. Central and South America Extracellular Vesicles Based Liquid Biopsy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Extracellular Vesicles Based Liquid Biopsy Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Extracellular Vesicles Based Liquid Biopsy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Bio-Techne Corporation Information
Table 35. Bio-Techne Description and Major Businesses
Table 36. Bio-Techne Product Features and Attributes
Table 37. Bio-Techne Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Bio-Techne Revenue Proportion by Product in 2024
Table 39. Bio-Techne Revenue Proportion by Application in 2024
Table 40. Bio-Techne Revenue Proportion by Geographic Area in 2024
Table 41. Bio-Techne Extracellular Vesicles Based Liquid Biopsy SWOT Analysis
Table 42. Bio-Techne Recent Developments
Table 43. Thermo Fisher Scientific Corporation Information
Table 44. Thermo Fisher Scientific Description and Major Businesses
Table 45. Thermo Fisher Scientific Product Features and Attributes
Table 46. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Thermo Fisher Scientific Revenue Proportion by Product in 2024
Table 48. Thermo Fisher Scientific Revenue Proportion by Application in 2024
Table 49. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2024
Table 50. Thermo Fisher Scientific Extracellular Vesicles Based Liquid Biopsy SWOT Analysis
Table 51. Thermo Fisher Scientific Recent Developments
Table 52. Qiagen Corporation Information
Table 53. Qiagen Description and Major Businesses
Table 54. Qiagen Product Features and Attributes
Table 55. Qiagen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Qiagen Revenue Proportion by Product in 2024
Table 57. Qiagen Revenue Proportion by Application in 2024
Table 58. Qiagen Revenue Proportion by Geographic Area in 2024
Table 59. Qiagen Extracellular Vesicles Based Liquid Biopsy SWOT Analysis
Table 60. Qiagen Recent Developments
Table 61. Exosome Diagnostics Corporation Information
Table 62. Exosome Diagnostics Description and Major Businesses
Table 63. Exosome Diagnostics Product Features and Attributes
Table 64. Exosome Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Exosome Diagnostics Revenue Proportion by Product in 2024
Table 66. Exosome Diagnostics Revenue Proportion by Application in 2024
Table 67. Exosome Diagnostics Revenue Proportion by Geographic Area in 2024
Table 68. Exosome Diagnostics Extracellular Vesicles Based Liquid Biopsy SWOT Analysis
Table 69. Exosome Diagnostics Recent Developments
Table 70. Aethlon Medical Corporation Information
Table 71. Aethlon Medical Description and Major Businesses
Table 72. Aethlon Medical Product Features and Attributes
Table 73. Aethlon Medical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Aethlon Medical Revenue Proportion by Product in 2024
Table 75. Aethlon Medical Revenue Proportion by Application in 2024
Table 76. Aethlon Medical Revenue Proportion by Geographic Area in 2024
Table 77. Aethlon Medical Extracellular Vesicles Based Liquid Biopsy SWOT Analysis
Table 78. Aethlon Medical Recent Developments
Table 79. System Biosciences Corporation Information
Table 80. System Biosciences Description and Major Businesses
Table 81. System Biosciences Product Features and Attributes
Table 82. System Biosciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. System Biosciences Recent Developments
Table 84. NanoSomix Corporation Information
Table 85. NanoSomix Description and Major Businesses
Table 86. NanoSomix Product Features and Attributes
Table 87. NanoSomix Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. NanoSomix Recent Developments
Table 89. Norgen Biotek Corporation Information
Table 90. Norgen Biotek Description and Major Businesses
Table 91. Norgen Biotek Product Features and Attributes
Table 92. Norgen Biotek Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Norgen Biotek Recent Developments
Table 94. Hitachi Chemical Corporation Information
Table 95. Hitachi Chemical Description and Major Businesses
Table 96. Hitachi Chemical Product Features and Attributes
Table 97. Hitachi Chemical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Hitachi Chemical Recent Developments
Table 99. Lonza Group Corporation Information
Table 100. Lonza Group Description and Major Businesses
Table 101. Lonza Group Product Features and Attributes
Table 102. Lonza Group Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Lonza Group Recent Developments
Table 104. Stemcell Technologies Corporation Information
Table 105. Stemcell Technologies Description and Major Businesses
Table 106. Stemcell Technologies Product Features and Attributes
Table 107. Stemcell Technologies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Stemcell Technologies Recent Developments
Table 109. Aruna Bio Corporation Information
Table 110. Aruna Bio Description and Major Businesses
Table 111. Aruna Bio Product Features and Attributes
Table 112. Aruna Bio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Aruna Bio Recent Developments
Table 114. Evomic Science Corporation Information
Table 115. Evomic Science Description and Major Businesses
Table 116. Evomic Science Product Features and Attributes
Table 117. Evomic Science Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Evomic Science Recent Developments
Table 119. Izon Science Corporation Information
Table 120. Izon Science Description and Major Businesses
Table 121. Izon Science Product Features and Attributes
Table 122. Izon Science Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Izon Science Recent Developments
Table 124. Exovita Biosciences Corporation Information
Table 125. Exovita Biosciences Description and Major Businesses
Table 126. Exovita Biosciences Product Features and Attributes
Table 127. Exovita Biosciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Exovita Biosciences Recent Developments
Table 129. Raw Materials Key Suppliers
Table 130. Distributors List
Table 131. Market Trends and Market Evolution
Table 132. Market Drivers and Opportunities
Table 133. Market Challenges, Risks, and Restraints
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Extracellular Vesicles Based Liquid Biopsy Product Picture
Figure 2. Global Extracellular Vesicles Based Liquid Biopsy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Blood-derived Liquid Biopsy Product Picture
Figure 4. Urine-derived Liquid Biopsy Product Picture
Figure 5. Saliva-derived Liquid Biopsy Product Picture
Figure 6. Other Product Picture
Figure 7. Global Extracellular Vesicles Based Liquid Biopsy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Therapeutic Monitoring
Figure 9. Medical Diagnostics
Figure 10. Biological Research
Figure 11. Other
Figure 12. Extracellular Vesicles Based Liquid Biopsy Report Years Considered
Figure 13. Global Extracellular Vesicles Based Liquid Biopsy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 15. Global Extracellular Vesicles Based Liquid Biopsy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Extracellular Vesicles Based Liquid Biopsy Revenue Market Share by Region (2020-2031)
Figure 17. Global Extracellular Vesicles Based Liquid Biopsy Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Blood-derived Liquid Biopsy Revenue Market Share by Player in 2024
Figure 20. Urine-derived Liquid Biopsy Revenue Market Share by Player in 2024
Figure 21. Saliva-derived Liquid Biopsy Revenue Market Share by Player in 2024
Figure 22. Other Revenue Market Share by Player in 2024
Figure 23. Global Extracellular Vesicles Based Liquid Biopsy Revenue Market Share by Type (2020-2031)
Figure 24. Global Extracellular Vesicles Based Liquid Biopsy Revenue Market Share by Application (2020-2031)
Figure 25. North America Extracellular Vesicles Based Liquid Biopsy Revenue YoY (2020-2031) & (US$ Million)
Figure 26. North America Top 5 Players Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) in 2024
Figure 27. North America Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) by Type (2020 - 2031)
Figure 28. North America Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) by Application (2020-2031)
Figure 29. US Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 30. Canada Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 31. Mexico Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 32. Europe Extracellular Vesicles Based Liquid Biopsy Revenue YoY (2020-2031) & (US$ Million)
Figure 33. Europe Top 5 Players Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) in 2024
Figure 34. Europe Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) by Type (2020-2031)
Figure 35. Europe Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) by Application (2020-2031)
Figure 36. Germany Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 37. France Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 38. U.K. Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 39. Italy Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 40. Russia Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Extracellular Vesicles Based Liquid Biopsy Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Top 8 Players Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) in 2024
Figure 43. Asia-Pacific Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) by Type (2020-2031)
Figure 44. Asia-Pacific Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) by Application (2020-2031)
Figure 45. Indonesia Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 46. Japan Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 47. South Korea Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 48. Australia Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 49. India Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 50. Indonesia Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 51. Vietnam Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 52. Malaysia Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 53. Philippines Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 54. Singapore Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2031) & (US$ Million)
Figure 55. Central and South America Extracellular Vesicles Based Liquid Biopsy Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Central and South America Top 5 Players Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) in 2024
Figure 57. Central and South America Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) by Type (2020-2031)
Figure 58. Central and South America Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) by Application (2020-2031)
Figure 59. Brazil Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2025) & (US$ Million)
Figure 60. Argentina Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2025) & (US$ Million)
Figure 61. Middle East and Africa Extracellular Vesicles Based Liquid Biopsy Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Middle East and Africa Top 5 Players Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) in 2024
Figure 63. South America Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) by Type (2020-2031)
Figure 64. Middle East and Africa Extracellular Vesicles Based Liquid Biopsy Revenue (US$ Million) by Application (2020-2031)
Figure 65. GCC Countries Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2025) & (US$ Million)
Figure 66. Israel Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2025) & (US$ Million)
Figure 67. Egypt Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2025) & (US$ Million)
Figure 68. South Africa Extracellular Vesicles Based Liquid Biopsy Revenue (2020-2025) & (US$ Million)
Figure 69. Extracellular Vesicles Based Liquid Biopsy Industry Chain Mapping
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
